To the Editor: Rosenberg et al. (Dec. 22 issue) document tumor responses in 11 patients with melanoma treated with interleukin-2 and tumor-infiltrating lymphocytes (TIL).1 These preliminary results are exciting and merit further clinical investigation. Biologic therapies can clearly induce striking antitumor responses. Whether higher response rates can be achieved with TIL than with other approaches involving interleukin-2 still requires further study. Given the limited number of patients in this study, it may be premature to state specific response rates, particularly without confidence intervals. More important, 40 patients underwent tumor biopsies so that TIL could be produced. Of these 40 patients,.
ASJC Scopus subject areas